Epigenomics is a molecular diagnostics company focusing on the development and commercialization of in vitro diagnostic tests for cancer.
Our cancer diagnostic tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma. These tests potentially address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros for diagnostics companies worldwide. Our lead test development program is in colorectal cancer. Further test are in development for lung and prostate cancer. Each of our products in development addresses either mass markets or high-value niches. While some of them lend themselves to partnering with established diagnostics industry players, others can be commercialized effectively by ourselves.
The concept of our diagnostic tests in development relies on detecting differences in DNA methylation patterns between healthy and sick individuals or between subgroups of patients for disease classification. We believe that we are an industry leader in DNA methylation technologies and biomarkers.
Industry partners as well as the medical and life science communities can access our intellectual property portfolio of over 60 granted any many more filed patents covering DNA methylation technologies and biomarkers as well as our DNA methylation expertise through research products, biomarker services, IVD development collaborations, and licensing.
Market capitalization (22-Sep-2017)
Closing share price (22-Sep-2017)